Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Alere Inc (ALR): This Diagnostics Business Could be A Good Play on Shareholder Activism

Since the beginning of the year, Alere Inc (NYSE:ALR) has experienced a significant gain of nearly 34.3%, handily beating the S&P 500’s return of only 11.7%. Moreover, it is also the target of recent shareholder activism by one of its largest shareholders, Coppersmith Capital Management. Coppersmith owns around a 5.8% stake in the company, and is urging the company to divest three of its businesses to unlock potential shareholder value. Is Alere a good buy now? Let’s take a look.

Among three business segments, HIS produced losses

Alere IncAlere Inc (NYSE:ALR) is considered the global leader in providing point-of-care diagnostics and services, with strong presence in toxicology, diabetes and infectious diseases, operating in three main business segments including Professional Diagnostics, Health Information Solutions (HIS) and Consumer Diagnostics. Most of its revenue, $2.19 billion, or 77.7% of the total revenue, was  generated from the Professional Diagnostics segment, while HIS and the Consumer Diagnostics segment contributed only $535.4 million and $93.5 million, respectively, in 2012 sales. The Professional Diagnostics segment was also the biggest profit contributor, with more than $243 million in operating income. While the Consumer Diagnostics generated $12.7 million in profit, HIS produced a loss of $73.4 million in 2012.

Unlocking shareholders’ value

In the recent letter to Alere Inc (NYSE:ALR)’s board, Coppersmith noted that it would nominate three candidates to the board at the company’s 2013 annual meeting. It suggested several steps to significantly improve the company’s operating performance, which could ultimately drive the share price much higher. First, Alere should divest several of its non-core businesses including HIS, the consumer diagnostics joint venture with P&G, and possibly the toxicology division. Coppersmith thought that the divestiture could be tax-free by first selling HIS for huge tax loss, and those divestments could produce more than $3 billion in proceeds.

As of March 2013, Alere Inc (NYSE:ALR) had nearly $3.5 billion in net debt and only $2.12 billion in equity. In the past twelve months, the company produced more than $590.6 million in EBITDA. Consequently, the business sales would result in only around $500 million in net debt, significantly lower the leverage ratio to less than 1 times its net debt/EBITDA. Last but not least, Coppersmith would like Alere to deliver around $50-$100 million in annual cost savings by bringing the SG&A margin to the historical level prior to the business expansion in the past two years and minimize the corporate overhead.

Is Alere cheap now?

Alere Inc (NYSE:ALR) is trading at around $24.50 per share, with the total market cap of $2 billion. The market values Alere at 9.4 times its trailing EBITDA. Compared to its peers, including Becton, Dickinson and Co. (NYSE:BDX) and Healthways, Inc. (NASDAQ:HWAY), Alere is not considered expensive. Becton, Dickinson and Company is trading at around $96 per share, with the total market cap of $18.7 billion. The market values the company at around 9.5 times its trailing EBITDA. Investors might be bullish about Becton, Dickinson and Co. (NYSE:BDX) due to the fact that Becton Dickinson Rx, the company’s subsidiary, just received FDA approval for the drug in the BD Simplist line of ready-to-administer pre-filled generic injectable, helping clinicians to simplify the procedures of traditional vial and syringe injection sequence, reducing potential medication error. The company reported that it planned for an additional 20-30 drugs in the BD Simplist product line in the next several years.

Healthways, Inc. (NASDAQ:HWAY) is the most expensively valued among the three. At $17 per share, it is worth around $580 million on the market. The market values Healthways at 14.6 times its trailing EBITDA. Healthways is the provider of specific and personalized interventions to help customers improve physical, emotional and their social well-being, operating in North America, Brazil and Australia. Recently, the company has been upgraded to “buy” by Piper Jaffray analyst Sean Wieland, as he thought Healthways could become the leader in the “population health management” industry. He also raised the company’s target price from $11 to $19 per share. He wrote, “Healthways is the domain expert in population health management, yet has less than a 1% market share in this $1 billion per year opportunity.” In the full year 2013, the company expected to generate $710-$750 million in revenue, with the EPS ranging from $0.25 to $0.35 per share.

My Foolish take

If Alere could sell their non-core businesses and bring more cash back, Alere’s balance sheet would be much stronger. Moreover, the company could focus its resources on its core business to drive the company forward. The expected $50-$100 million in annual savings could also affect its bottom line quite positively in the next several years. Indeed, Alere could be considered a buy at its current price.

Anh HOANG has no position in any stocks mentioned. The Motley Fool recommends Becton Dickinson.

The article This Diagnostics Business Could be A Good Play on Shareholder Activism originally appeared on and is written by Anh HOANG.

Anh is a member of The Motley Fool Blog Network — entries represent the personal opinion of the blogger and are not formally edited.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.